All In Biotech

Drug Trial Radar · NCT05353257

A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer

A Randomized, Double-Blind, International Multicenter, Phase III Study to Evaluate the Anti-Tumor Efficacy and Safety of Serplulimab or Placebo in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer

Last checked: Nov 19, 2026Latest source record: Jan 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 511 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

511

Actual

Start

May 17, 2022

Primary completion

Jun 30, 2026

Study completion May 30, 2028

Sponsor

Lead sponsor
Shanghai Henlius BiotechIndustry
Sponsor type
Industry
First posted
Apr 29, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a randomized, double-blind, multicenter, phase III clinical study to compare the clinical efficacy and safety of Serplulimab + chemotherapy+ concurrent radiotherapy vs chemotherapy+ concurrent radiotherapy in subjects with Limited-Stage Small Cell Lung Cancer.

Conditions

  • Limited-Stage Small Cell Lung Cancer

Interventions

  • HLX10Drug

    Serplulimab is an innovative monoclonal antibody targeting PD-1,developed by Shanghai Henlius Biotech, Inc. 300mg Q3W

  • carboplatin/cisplatin-etoposideDrug

    Etoposide: 100 mg/m2, IV, on Days 1, 2, and 3 of each cycle. Carboplatin: AUC = 5, IV, on Day 1 of each cycle up to a dose of 750 mg. investigator's choice. Cisplatin: 75mg/m2, IV, on Days 1 of each cycle. investigator's choice.

  • Thoracic radiotherapyRadiation

    Standard Thoracic Radiotherapy

  • PlaceboDrug

    Placebo Q3W

  • Prophylactic Cranial Irradiation (PCI)Radiation

    PCI will be strongly recommended for participants who achieve CR or PR after completion of chemoradiation treatment.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survival (PFS)Time frame: up to approximately 24months
  2. Overall survival (OS)Time frame: up to 36 months

Locations

129 sites in 11 countries. Site status is shown where the registry gives one.

  • OPN-Glendale

    Arcadia, California

  • OPN-Los Alamitos

    Los Alamitos, California

  • Southern California Permanente Group

    Los Angeles, California

  • Emad Ibrahim, MD, Inc

    Redlands, California

  • Providence Medical Foundation

    Santa Rosa, California

  • Lutheran Medical Center - Cancer Centers of Colorado

    Golden, Colorado

  • Eastern Connecticut Hematology & Oncology Associates

    Norwich, Connecticut

  • Cancer Specialists of North Florida

    Jacksonville, Florida

  • Mid Florida Hematology and Oncology Center

    Orange City, Florida

  • Advent Health Orlando

    Orlando, Florida

  • Napa Research

    Pompano Beach, Florida

  • Kansas University Mediacal Center

    Fairway, Kansas

  • Pontchartrain Cancer Center

    Covington, Louisiana

  • Tulane University

    New Orleans, Louisiana

  • Health Partners

    Bloomington, Minnesota

  • Renown Health

    Reno, Nevada

  • Dartmouth Hitchcock Medical Center

    Lebanon, New Hampshire

  • New York City Health+HospitalsCorporation Elmhurst Hospital Center

    Elmhurst, New York

  • Northwell Health

    Queens, New York

  • Montefiore Medical Center

    The Bronx, New York

  • Cleveland Clinic Mercy Hospital

    Canton, Ohio

  • Gabrail Cancer Center

    Canton, Ohio

  • Tricounty Hematology and Oncology Associates

    Massillon, Ohio

  • Kaiser Permanente Northwest

    Portland, Oregon

  • The Center for Cancer and Blood Disorders

    Fort Worth, Texas

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas

  • Millennium Research & Clinical Development

    Houston, Texas

  • Pro Research Tools, INC DBA Lumi Research

    Kingwood, Texas

  • The University of Texas - Hope Cancer Center

    Tyler, Texas

  • Innova Schar Cancer Insitute

    Fairfax, Virginia

  • Northwest Medical Specialties

    Tacoma, Washington

  • Klinikum Klagenfurt am Worthersee

    Klagenfurt, Austria

  • Klinikum Klagenfurt am Wörthersee

    Klagenfurt, Austria

  • Karl Landsteiner Institut für Lungenforschung und pneumologische Onkologie, c/o Klinik Floridsdorf Abteilung für Innere Medizin und Pneumologie

    Vienna, Austria

  • Karl Landsteiner Institute for Lung Research and Pneumological Oncology, c/o Klinik Floridsdorf Department for Inner Medicine und Pneumology

    Vienna, Austria

  • The First Affiliated Hospital of Bengbu Medical College

    Bengbu, Anhui, China

  • Anhui Chest Hospital

    Hefei, Anhui, China

  • Cancer Hospital Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, China

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China

  • The First Affiliated Hospital of Chongqing Medical

    Chongqing, Chongqing Municipality, China

Showing 40 of 129 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.